Education
About Us
Working with TipRanks
Follow Us
Lyra Therapeutics (LYRA)
NASDAQ:LYRA
Total Valuation
Lyra Therapeutics has a market cap or net worth of $6.73M. The enterprise value is $520.38K.
Market Cap$6.73M
Enterprise Value$520.38K
Share Statistics
Lyra Therapeutics has 65.88M shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding65.88M
Owned by Insiders9.11%
Owned by Instutions25.37%
Financial Efficiency
Lyra Therapeutics’s return on equity (ROE) is -8.06 and return on invested capital (ROIC) is -166.52%.
Return on Equity (ROE)-805.89%
Return on Assets (ROA)-140.83%
Return on Invested Capital (ROIC)-166.52%
Return on Capital Employed (ROCE)-179.37%
Revenue Per Employee$49,033.333
Profits Per Employee-$3,253,733.333
Employee Count30
Asset Turnover0.02
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Lyra Therapeutics is -0.14. Lyra Therapeutics’s PEG ratio is -0.01.
PE Ratio-0.14
PS Ratio8.76
PB Ratio1.16
Price to Fair Value1.16
Price to FCF-0.19
Price to Operating Cash Flow-0.19
PEG Ratio-0.01
Income Statement
In the last 12 months, Lyra Therapeutics had revenue of $1.47M and earned -$97.61M in profits. Earnings per share was -$1.53.
Revenue$1.47M
Gross Profit-$12.01M
Operating Income-$101.42M
Pretax Income-$97.56M
Net Income-$97.61M
EBITDA-67.04M
Earnings Per Share (EPS)-1.53
Cash Flow
In the last 12 months, operating cash flow was -$77.72M and capital expenditures -$3.18M, giving a free cash flow of -$80.90M billion.
Operating Cash Flow-$77.72M
Free Cash Flow-$80.90M
Free Cash Flow per Share-$1.23
Dividends & Yields
Lyra Therapeutics pays an annual dividend of , resulting in a dividend yield of
Dividend Per Share
Dividend Yield
Payout Ratio
Free Cash Flow Yield-538.33%
Earnings Yield-695.23%
Stock Price Statistics
Beta0.80
52-Week Price Change-98.10%
50-Day Moving Average0.17
200-Day Moving Average0.23
Relative Strength Index (RSI)32.66
Average Volume (3m)1.30M
Important Dates
Lyra Therapeutics upcoming earnings date is May 13, 2025, After Close.
Last Earnings DateMar 13, 2025
Next Earnings DateMay 13, 2025
Ex-Dividend Date―
Financial Position
Lyra Therapeutics as a current ratio of 3.41, with Debt / Equity ratio of 2.97
Current Ratio3.41
Quick Ratio3.41
Debt to Market Cap2.56
Net Debt to EBITDA0.06
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Lyra Therapeutics has paid $50.00K in taxes.
Income Tax$50.00K
Effective Tax Rate0.04%
Enterprise Valuation
Lyra Therapeutics EV to EBITDA ratio is -0.08, with an EV/FCF ratio of -0.10.
EV to Sales4.72
EV to EBITDA-0.08
EV to Free Cash Flow-0.10
EV to Operating Cash Flow-0.10
Balance Sheet
Lyra Therapeutics has $51.63M in cash and marketable securities with $35.32M in debt, giving a net cash position of -$16.30M billion.
Cash & Marketable Securities$51.63M
Total Debt$35.32M
Net Cash-$16.30M
Net Cash Per Share-$0.25
Tangible Book Value Per Share$0.18
Margins
Gross margin is 100.00%, with operating margin of -6280.83%, and net profit margin of -6090.94%.
Gross Margin100.00%
Operating Margin-6280.83%
Pretax Margin-6088.40%
Net Profit Margin-6090.94%
EBITDA Margin-6280.83%
EBIT Margin0.00%
Analyst Forecast
The average price target for Lyra Therapeutics is $2.00, which is 11.43% higher than the current price. The consensus rating is Hold
Price Target$2.00
Price Target Upside1900.00%
Analyst ConsensusHold
Analyst Count2
Revenue Growth Forecast-1.54%
EPS Growth Forecast-7.20%